Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-31
2007-07-31
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S504000, C540S505000, C540S507000, C540S509000, C540S510000, C540S512000, C540S514000
Reexamination Certificate
active
10479000
ABSTRACT:
The invention concerns novel benzodiazepine derivatives and their uses in the field of therapeutics particularly for treating pathologies involving the activity of a cyclic nucleotide phosphodiesterase. It also concerns methods for preparing them and novel synthesis intermediates. The inventive compounds more particularly correspond to general formula (I):
REFERENCES:
patent: 3182067 (1965-05-01), Fryer et al.
patent: 3398159 (1968-08-01), Berger et al.
patent: 3631029 (1971-12-01), Yamamoto et al.
patent: 20 17 060 (1970-10-01), None
patent: 17 95 832 (1976-04-01), None
patent: 0 065 229 (1982-11-01), None
patent: 0 387 618 (1990-09-01), None
patent: 0 552 665 (1993-07-01), None
patent: 7 666 (1970-02-01), None
patent: 2 085 645 (1971-12-01), None
patent: 2 273 547 (1976-01-01), None
patent: 972963 (1964-10-01), None
patent: WO 97/28135 (1997-08-01), None
patent: WO 97/34878 (1997-09-01), None
patent: WO 00/79263 (2000-12-01), None
patent: WO 02/51838 (2002-07-01), None
Sotiriadis et al, “New synthesis of substituted 3,5-dihydro-4H-2,3-benzodiazepin-4-ones”, CS 81:152197 & J. Heterocycl. Chem. (1974), 11(3), pp. 401-403, XP-002191653.
Flammang, “2,3-Benzodiazepines: 2-amino-3-isoquinolinones from ring contraction of 4-oxo-2,3-benzodiazepines”, CS 93:167330 & C.R. Seances Acad. Scie., Ser. C (1980), 290(17), pp. 349-351, XP-002191655.
Bogza et al, “Recyclization of 2-oxobenzo[c]pyrrole[3,2-e]pyrylium perchlorates by acid hydrazides”, CS 124:343246 & Khim. Geterotsikl Soedin, (1995), (12), pp. 1691-1692, XP-002191656.
Bogza et al, “Synthesis of benzo[c]pyrylium salts from 2-(3,4-dimethoxyphenyl)succinic acid derivatives and their transformations”, CS 126:7948 & Zh. Org. Khim. (1996), 32(4), pp. 596-603, XP-002191657.
“3H-2,3-Benzodiazepine-5-acetamide, 3-(aminocarbonyl)-4,5-dihydro-7,8-dimethoxy-1-methyl-4-oxo-N-phenyl”, Chemcats 2001-2609076 and Ambinter: Exploratory Library, May 31, 2001.
“4H-2,3—Benzodiazepin-4-one, 3-[2-(diethylamino)ethyl]-3,5-dihydro-7,8-dimethoxy-1-methyl-(9CI)”, CA 48202-61-5 Registry, 1984.
Shimamoto et al, “Pharmacological Screening of New Benzodiazepines in Mice”, Journal of the Takeda Research Laboratories, Osaka, JP, vol. 29, No. 1, 1970, pp. 134-144.
Gatta et al, “Derivatives of 2,3-Benzodiazepine”, Il Farmaco, Rome IT, vol. 40, No. 12, 1985, pp. 942-955.
Sotiriadis et al, “New Synthesis of Substituted 3,5-Dihydro-4H-2,3-benzodiazepine-4-ones”, J. Heterocycl. Chem. (1974), 11(3), pp. 401-403.
Flammang et al, “2,3-Benzodiazepine systems. II. 4-Oxo-3,5-dihydro(4H)-2,3-benzodiazepines. Synthesis and pharmacological study”, CA 85:46605 & Eur. J. Med. Chem.—Chim. Ther. (1976), 11(1), pp. 83-87.
Flammang, “2,3—Benzodiazepines: 2-amino-3-isoquinolinones from ring contraction of 4-oxo-2,3-benzodiazepines”, CS 93:167330 & C.R. Seances Acad. Sci., Ser. C (1980) 290(17), pp. 349-351.
De Sarro et al, “Synthesis and anticonculsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists”, Farmaco, Society Chimica Italiana, Pavia, IT., vol. 54, No. 3, 1999, pp. 178-187.
Nagarajan et al, “Derivatives of 3,5-Dihydro-4H-benzo [2,3] diazepin-4-one”, J Med. Chem. (1972), 15(10), pp. 1091-1092.
Bogza et al, “Synthesis of benzo[c]pyrylium salts from 2-(3,4-dimethoxyphenyl)succinic acid derivatives and their transformations”, CA 126:7948 & Zhurnal Organicheskoi Khimii (1996), 32(4), pp. 596-603.
Chimirri et al, “1-Aryl-3,5-dihydro-4H-2,3-benzoidiazepin-4-ones: Novel AMPA Receptor Antagonists”, J. Med. Chem. (1997), 40(8), pp. 1258-1269.
Chimirri et al, “3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: A New Class of AMPA Receptor Antagonists”, J. Med. Chem. (1998), 41(18), pp. 3409-3416.
CA BAS 0340144 and “AsinEx Compound Collection”, May 10, 2001, Asinex, 6 Shukinskaya Street, Moscow, 123182, Russia.
Sugasawa et al, “1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressent actions”, Journal of Medical Chemistry, American Chemical Society, Washington, US, vol. 28, No. 6, 1985, pp. 699-707.
Vassilev et al, “Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors”, CA 136:226419 & Anti-Cancer Drug Design (2001), 16(1). pp. 7-17.
Bogatskii et al, “Predicting the pharmacological activities of tranquilizers which are 1,4-diazepin-2-one derivatives”, CS 95:180658 & USP. Kvantovoi Khim. Kvantovoi Biol., Tr. Mezhdunar. Konf. (1980), Meeting Date 1978, vol. 2, 33-40. Editor(s): Petrov, E.G.; Loewdin, Per Olov, Zener, M. Publisher: Izd, Naukova Dumka, Kiev, USSR.
Combs et al, “Phosphoryl chloride-induced ring contraction of 1,4-benzodiazepinones to (chloromethyl)quinazolines” Journal of Heterocyclic Chemistry (1986), 23(4), pp. 1263-1264.
Ivanov, “1-4-Benzodiazepines. V. Synthesis of 7,8-dimethoxy-5-[6,′,7′-dimethoxyisoquinolyl]-1,3-dihydro-2H-1,4b enzodiazepin-2-ones”, CS 86:189880 & Khim.-Farm. Zh. (1977), 11(2), pp. 32-36.
Compton et al, The Lancet, vol. 358, Jul. 28, 2001, pp. 265-270.
Houslay et al, DDT, vol. 10, No. 22, Nov. 2005, pp. 1503-1519.
O'Donnell et al, TRENDS in Pharmacological Sciences, vol. 25, No. 3, Mar. 2004, pp. 158-163.
Teixeira et al, TiPS, May 1997, vol. 18, pp. 164-170.
Barad et al, Proc. Natl. Acad. Sci., vol. 95, Dec. 1998, pp. 15020-15025.
Torphy et al, Am. J. Respir. Crit. Care Med., vol. 157, 1998, pp. 351-370.
Bourguignon Jean-Jacques
Klotz Eveline
Lagouge Yan
Lugnier Claire
Macher Jean-Paul
Coleman Brenda
Via Pharmaceuticals, Inc.
LandOfFree
Cyclic nucleotide phosphodiesterase inhibitors, preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic nucleotide phosphodiesterase inhibitors, preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic nucleotide phosphodiesterase inhibitors, preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3778145